Lenvatinib (LENVIMA)
Renal Cell Carcinoma
Regulatory ReviewApplication Submitted in Japan for combo with belzutifan
Key Facts
Indication
Renal Cell Carcinoma
Phase
Regulatory Review
Status
Application Submitted in Japan for combo with belzutifan
Company
About Eisai
Eisai is a fully integrated, patient-centric biopharmaceutical company with a mission to give first thought to patients and their families. Its strategic focus on neurology and oncology has yielded landmark achievements, most notably the commercialization of the first disease-modifying Alzheimer's therapy, LEQEMBI, in partnership with Biogen. The company complements its commercial success with a deep, long-standing commitment to sustainability and global health, distributing billions of treatments for neglected tropical diseases. Financially robust and strategically disciplined, Eisai is leveraging its neuroscience leadership to expand its oncology portfolio and solidify its long-term growth trajectory.
View full company profileOther Renal Cell Carcinoma Drugs
| Drug | Company | Phase |
|---|---|---|
| LW-02 Immunopheresis | Immunicom | Phase 2 |
| CB-839 (Telaglenastat) | Calithera Biosciences | Phase 2 |
| XS008 (axitinib) | Xspray Pharma | Preclinical/Development |
| CDK7 allosteric inhibitor | Acellera | Pre-clinical |
| Precision Oncology - RCC | ReviveMed | Discovery |
| Cabozantinib | Exelixis | Phase 3 |
| Zanzalintinib (XL092) | Exelixis | Phase 3 |
| Casdatifan (AB521) | Arcus Biosciences | Phase 3 |
| XmAb®819 | Xencor | Phase 1 |